![Maria Carmen De Santis: Significance of HER2-Low in DCIS of the breast](https://oncodaily.com/pub/uploads/2024/07/1920_stockphotoofapersonwearingabreastcancerribbon-1-1280x854.jpg)
Maria Carmen De Santis: Significance of HER2-Low in DCIS of the breast
Maria Carmen De Santis, Radiation Oncologist at National Cancer Institute, Milan, shared on X:
“Significance of HER2-Low in DCIS How might it impact on clinical practice in the foreseeable future?
Knowledge that DCIS with low HER2 expression is associated with less aggressive features could inform less aggressive future therapeutic interventions.”
Source: Maria Carmen De Santis/X
Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast.
Authors: Chiara M. Ciniselli, Paolo Verderio, Paolo Baili, Milena Sant, Sara Pizzamiglio, Valeria Duroni, Filippo G. de Braud, Secondo Folli, Gianfranco Scaperrotta, Maria C. De Santis, Giovanni Apolone, Cinzia De Marco, Andrea Vingiani, Vera Cappelletti, Giancarlo Pruneri, and Serena Di Cosimo.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023